Frontage offers full-service radiolabeled human C14 AME (hAME) studies to support your drug development programs.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage's Clinical and DMPK teams work together seamlessly to provide full-service radiolabeled human C14 AME (hAME) studies. Experience the benefits and added value of Frontage’s complete suite of clinical and analytical services for hAME studies - seamless conduct and precise analysis by the most client-focused experts in the industry.
Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."
Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion, metastasis, disease progression and mortality, thus serving as a novel cancer biomarker. In this paper, we develop and validate an LC-MS/MS method for the quantification of fascin proteins in human serum.